
Dr Menelas Nkeshimana
MBBS (Hons.), MMED (Internal Medicine), MSc. (Global Health Delivery) Ministry of Health, Republic of Rwanda
Making of the first fully African-owned, developed, clinically-evaluated, regulated and end-to-end manufactured vaccine
Sub-Saharan Africa faces its 13th Ebola outbreak in a decade, and there is no broadly protective vaccine available to prevent further epidemics by this or other filoviruses. Several species are known (Ebola/Zaire, Sudan and Bundibugyo virus and a distant relative, Marburg virus), but currently the only available vaccine targets Ebola/Zaire. Another disease, mpox, circulates in filovirus affected regions, and the effective vaccine is too expensive for many African Union Member States, creating a need for an affordable biosimilar or improved ‘bio-better.’
Egypt’s Minapharm Group is developing a multivalent, broadly protective pan-filovirus vaccine with inherent mpox efficacy, based on its proprietary viral vector platform. It will offer protection against mpox, the three Ebolas and Marburg alike.
The science behind the vaccine
Modified Vaccinia Ankara (MVA) is a highly attenuated, non replicating viral vector with a well-established safety profile even in immunocompromised individuals and has a large packaging capacity for multivalency.
MVA-CR19, Minapharm’s IP-protected MVA strain, has improved yields in a robust and sustainable manufacturing platform. An innovative system for rapid generation of vectors adapted to specific outbreak situations supports rapid-response vaccines, such as the candidate against Bundibugyo virus (BDBV).
End-to-end vaccine manufacturing will take place at Minapharm’s state of-the-art New Cairo facility, which is finalised and ready for production
MVA-CR19 is manufactured on Minapharm’s proprietary continuous avian suspension cell line AGE1. CR.pIX in chemically defined medium and purified by filtration-based processes. This enables industrial scalability, seamless transfer and regional sustainable vaccine manufacture. The novel vaccine will cost a fraction of the current mpox vaccine and is furthermore aimed at providing additional protection against all known Ebola and Marburg diseases.
An all-African vaccine
The Rwanda headquartered African Medicines Agency (AMA) is coordinating vaccine licensure with the European Medicines Agency (EMA), Egyptian Drug Authority (EDA), Rwanda Food and Drugs Authority (RFDA) and World Health Organization (WHO) under a joint emergency use listing (EUL) pathway.
End-to-end vaccine manufacturing will take place at Minapharm’s state of-the-art New Cairo facility, which is finalised and ready for production. EDA approved the site for drug product manufacturing on 7 October, 2026. Rwanda stands ready to host the Phase I clinical trials as soon as the respective approvals are obtained. The project is led by Minapharm and undertaken in partnership with Bayer AG, Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI).
Global Cause